Sfoglia per AUTORE
TESSOULIN B
Collezione AOU Alessandria
Items : 2
Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. in Haematologica / Haematologica. 2025 Apr 1;110(4):1048-1049. doi: 10.3324/haematol.2024.287031. Epub 2025 Apr 1.
2025
AOU Alessandria
AOU Alessandria
Iannitto E; Ferrero S; Bommier C; Drandi D; Ferrante M; Bouabdallah K; Carras S; Gini G; Camus V; Mancuso S; Marcheselli L; Ferrari A; Merli M; Tessoulin B; Stelitano C; Beldjord K; Roti G; Jardin F; Castagnari B; Palombi F; Baseggio L; Traverse-Glehen A; Tripodo C; Liberati AM; Parolini M; Usai S; Patti C; Federico M; Musso M; et alii...
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. in Haematologica / Haematologica. 2024 Aug 1;109(8):2564-2573. doi: 10.3324/haematol.2023.283918.
2024
AOU Alessandria
AOU Città della Salute di Torino
AOU Alessandria
AOU Città della Salute di Torino
Bertoni F; Cavalli F; Landi F; Spina M; Re F; Pietrantuono G; Merli M; Houot R; Liberati AM; Haioun C; Devizzi L; Cartron G; Casasnovas RO; Angrilli F; Occhini U; Pulsoni A; Celli M; Califano C; Capochiani E; Cabras MG; Zanni M; Tilly H; Tessoulin B; Conconi A; Palombi F; Cavallo F; Morschhauser F; Gressin R; Marino D; et alii...